The U.S. Food and Drug Administration (FDA) approved the use of Juvéderm Voluma XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. The use of a cannula allows for the injection of Juvéderm Voluma XC in the cheek area with natural results and beautiful precision. The TSK STERiGLIDE™ has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement.

At Leah Nickie Advanced Aesthetics we have been using this method for years and have perfected the use of cannulas for fillers. Now the technique of cannula injection is being nationally recognized as the most preferred method for the best results.

“As a physician specializing in facial structure and rejuvenation, I am very happy to see this receive FDA approval. For fillers in the mid-face, there is no better approach than the use of cannulas. We have been using cannulas for several years and find they help achieve smoothly sculpted results with much less bruising. ” said Dr. Julie Seaman, a Board Certified Physician and Medical Director for Leah Nickie Advanced Aesthetics.

"At Allergan, we are committed to driving innovation in medical aesthetics as well as providing best-in-class injector training to our customers," says Carrie Strom, Senior Vice President of U.S. Allergan Medical Aesthetics. "With this approval, Allergan will be able to educate on facial anatomy and injection techniques that will help healthcare providers administer treatment with Juvéderm Voluma XC safely to achieve optimal patient satisfaction."

A multicenter, split-face, investigator-blinded, non-inferiority study was performed to assess the safety and effectiveness of Juvéderm Voluma XC for correction of age-related volume deficit in the mid-face with the use of a TSK STERiGLIDE™ cannula versus a needle. The 12-week study took place in seven sites across the U.S. with 60 subjects.

Within the Juvéderm Collection of Fillers, this is the first approval for the use of cannula. Juvéderm Voluma XC was first approved by the FDA in 2013 and is formulated with Allergan's proprietary VYCROSS® technology, which blends different molecular weights of hyaluronic acid, contributing to the gel's duration and is proven to last in the mid-face area for up to 24 months with optimal treatment. Juvéderm Voluma XC is currently the best-selling Juvéderm product in the US.

Reach out to info@leahnickie.com if you want to set up a consultation appointment and learn more about facial fillers and the use of cannulas.